Icotinib is an active treatment of non-small-cell lung cancer: a retrospective study.
BACKGROUND
Icotinib hydrochloride is a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) with preclinical and clinical activity in non-small cell lung cancer (NSCLC). This retrospective analysis was performed to assess the efficacy of icotinib on patients with non-small-cell lung cancer (NSCLC).


METHODS
82 consecutive patients treated with icotinib as first (n = 24) or second/third line (n = 58) treatment at three hospitals in Nanjing were enrolled into our retrospective research. The Response Evaluation Criteria in Solid Tumors (RECIST) was used to evaluate the tumor responses and the progression-free survival (PFS) and overall survival (OS) was evaluated by the Kaplan-Meier method.


RESULTS
Median PFS was 4.0 months (95% CI 2.311-5.689). Median OS was 11.0 months (95% CI 8.537-13.463) in this cohort. Median PFS for first and second/third line were 7.0 months (95% CI 2.151-11.8) and 3.0 months (95% CI 1.042-4.958), respectively. Median OS for first and second/third line were 13.0 months (95% CI 10.305-15.695) and 10.0 months (95% CI 7.295-12.70), respectively. In patients with EGFR mutation (n = 19), icotinib significantly reduced the risk of progression (HR 0.36, 95% CI 0.18-0.70, p = 0.003) and death (HR 0.10, 95% CI 0.02-0.42, p = 0.002) compared with those EGFR status unknown (n = 63). The most common adverse events were acne-like rash (39.0%) and diarrhea (20.7%).


CONCLUSIONS
Icotinib is active in the treatment of patients with NSCLC both in first or second/third line, especially in those patients harbouring EGFR mutations, with an acceptable adverse event profile.
Department of Oncology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Xiaofeng
X
Chen
Department of Cardiothoracic Surgery, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Quan
Q
Zhu
Department of Oncology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Yiqian
Y
Liu
Department of Oncology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Ping
P
Liu
Department of Oncology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Yongmei
Y
Yin
Department of Oncology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Renhua
R
Guo
Department of Oncology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Kaihua
K
Lu
Department of Oncology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Yanhong
Y
Gu
Department of Oncology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Lianke
L
Liu
Department of Oncology, Jinling Hospital, Nanjing University School of Medicine, Nanjing, China.
Jinghua
J
Wang
Department of Oncology, the Second Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Zhaoxia
Z
Wang
Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway; Norwegian University of Science and Technology, Trondheim, Norway, Cancer Clinic, Levanger Hospital, Nord-Trøndelag Health Trust, Levanger, Norway.
Oluf Dimitri
OD
Røe
Department of Oncology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Yongqian
Y
Shu
Department of Oncology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Lingjun
L
Zhu
D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D002681:China; D043844:Crown Ethers / Q000627:therapeutic use*; D018572:Disease-Free Survival; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D006801:Humans; D053208:Kaplan-Meier Estimate; D008875:Middle Aged; D011799:Quinazolines / Q000627:therapeutic use*; D012189:Retrospective Studies; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D043844:Crown Ethers; D011799:Quinazolines; C531470:icotinib; D066246:ErbB Receptors